TN

Tarak Nath Saha

Active Director Director DIN 11860384
DIN 11860384 First appointment Jul 2026
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Jul 2026
Shareholding value β€’β€’β€’β€’ Premium profile

About Tarak Nath Saha

Tarak Nath Saha is a Director at Linet Pharmaceuticals Private Limited (since 2026).

DIN 11860384
Primary Designation Director
First Appointment 29 Jul 2026

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director29 Jul 20262026Active

Board colleagues of Tarak Nath Saha

NameDINCompanyDesignation
Bijoyendu Saha11860383Linet Pharmaceuticals Private LimitedDirector
Saibal BhattacharyaLinet Pharmaceuticals Private LimitedIndividual Subscriber
Subrata Ghosh11860385Linet Pharmaceuticals Private LimitedDirector

Directorship timeline

Open interactive timeline →
Linet Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Tarak Nath Saha

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Tarak Nath Saha

Tarak Nath Saha currently holds 1 directorship: Linet Pharmaceuticals Private Limited (Director, since 29 Jul 2026).

Tarak Nath Saha was first appointed on 29 Jul 2026 as Director at Linet Pharmaceuticals Private Limited.

The current boards of Tarak Nath Saha's companies include Bijoyendu Saha (Linet Pharmaceuticals Private Limited), Saibal Bhattacharya (Linet Pharmaceuticals Private Limited), Subrata Ghosh (Linet Pharmaceuticals Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available